Literature DB >> 10621883

Concordance of primary generalised epilepsy and carbamazepine hypersensitivity in monozygotic twins.

S G Edwards1, V Hubbard, S Aylett, D Wren.   

Abstract

In this paper we describe the previously unreported phenomenon of a carbamazepine-induced mucocutaneous syndrome in identical twins. These twins had developed primary generalised epilepsy within 2 months of each other.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10621883      PMCID: PMC1741403          DOI: 10.1136/pgmj.75.889.680

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  6 in total

Review 1.  Safety and tolerability of antiepileptic drug treatment in children with epilepsy.

Authors:  Renzo Guerrini; Gaetano Zaccara; Giancarlo la Marca; Anna Rosati
Journal:  Drug Saf       Date:  2012-07-01       Impact factor: 5.606

Review 2.  Gene polymorphisms and their role in epilepsy treatment and prognosis.

Authors:  Ortrud K Steinlein
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-06-16       Impact factor: 3.000

Review 3.  Genetic factors in the predisposition to drug-induced hypersensitivity reactions.

Authors:  Munir Pirmohamed
Journal:  AAPS J       Date:  2006-02-03       Impact factor: 4.009

4.  The Absence of CYP3A5*3 Is a Protective Factor to Anticonvulsants Hypersensitivity Reactions: A Case-Control Study in Brazilian Subjects.

Authors:  Luciana Kase Tanno; Daniel Shikanai Kerr; Bernardo dos Santos; Leda Leme Talib; Célia Yamaguti; Helcio Rodrigues; Wagner Farid Gattaz; Jorge Kalil
Journal:  PLoS One       Date:  2015-08-20       Impact factor: 3.240

Review 5.  The promise of new antiepileptic drugs.

Authors:  John S Duncan
Journal:  Br J Clin Pharmacol       Date:  2002-02       Impact factor: 4.335

6.  Specific safety and tolerability considerations in the use of anticonvulsant medications in children.

Authors:  Amy Z Crepeau; Brian D Moseley; Elaine C Wirrell
Journal:  Drug Healthc Patient Saf       Date:  2012-06-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.